|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.2795 - 1.3400|
|52 Week Range||0.7740 - 5.0626|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo. Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. Company will develop full protocols and manage Investigational New Drug (IND) application on behalf of Vireo and will work with the FDA towards approvals.
After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.
Aurora Cannabis (NYSE: ACB) (TSX: ACB) announced the launch of Ready for Edibles, a national bilingual campaign to educate new and experienced cannabis consumers on responsible consumption and safe storage of edibles products before they become available for sale in December. Core One Labs (CSE: COOL) (OTCQX: CLABF) (Frankfurt: LD6) announced that its board of directors […]The post Cannabis Stock News Roundup October 31 appeared first on Market Exclusive.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...